Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Trial abstract · §5

KISS-PH2-HSDD — citing documents

Every Institute document that draws on this record.

Document identifier
CEI-TR-0143/5
Series
Trial abstract
Version
2.2
Published
09 Jan 2023
Last reviewed
09 Nov 2023
Next review
09 Nov 2025
Identifier
10.71829/cei.trial.143
Certainty
Low
Cycle
2023 Q1
Phase
Phase 2
Status
Reported

§5Citing documents

This page records every Institute document that draws on KISS-PH2-HSDD. A trial abstract is a node in the document set rather than a leaf: it is cited by the monographs that use its estimate and by the syntheses that include it, and those citations are listed here so that the flow of an estimate through the document set can be followed in both directions.

§5.1Monograph evidence extracts

Table 7. Monograph evidence extracts that draw on this trial.

§5.2Evidence syntheses

No evidence synthesis includes this record among its contributing studies.

§5.3Other records in the same programme

This record does not belong to a programme with other records in the Institute's set.

§5.4Reference

The Institute holds no publication reference for this trial. Where a trial is real and its report has not been obtained, the record says so rather than citing a source it does not hold.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.